Utah Cancer Specialists
Last Updated January 1, 2022
Protoccol Number
BRE009 Breast A Phase III Randomised Study Assessing the Efficacy andSafety of Study Drug+ Paclitaxel Versus Placebo + Paclitaxel as First-lineTreatment for Patients with Locally Advanced (Inoperable) or Metastatic ER PR negative HER2+ Triple Negative Breast Cancer NCT03997123
BRE011 Breast A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Study Drug plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy NCT04752332
BRE012 Breast EMBER-3: A Randomized, Open-Label, Phase 3 Study of Study Drug vs Investigator’s Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy NCT04975308
BIDU002 Bile Duct A Pivotal Study of a Study Drug in Patients with Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2 gene Fusions or FGFR2 Gene Mutations or Amplifications NCT03230318
BIDU001 Bile Duct A Phase 3, Open-Label, Randomized Study of Study Drug Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of
Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements		 NCT04093362
GAS003 Gastric A Phase 3 Double-Blind, Randomized Study Drug Plus CAPOX Compared with Placebo Plus CAPOX as 1 Line Treatment of Subjects with Claudin18.2+, HER2-Phase 2/3 Trial to Evaluate Study Drug in Combination With Study Drug and Chemotherapy or Study Drug and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer NCT04082364
GAS002 Gastric A Phase 3 Double-Blind, Randomized Study Drug Plus CAPOX Compared with Placebo Plus CAPOX as 1 L Treatment of Subjects with Claudin18.2+, HER2-Negative,Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction NCT03653507
MYE002 Myelofibrosis A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Study Drug in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis NCT04468984
HEA001 Head and Neck A phase 3 Study of a Study Drug in Combination with Paclitaxel, in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT04338399
HEA002 Head and Neck Phase 3 study of Study Drug in combination with platinum-based chemotherapy and standard fractionation intensity modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck NCT04459715
LYM005 CLL-SLL-NHL A Phase 1/2 Study of Study Drug in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) NCT03740529
LYM004 Lymphona  A Study of Study Drug Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed-Refractory, Follicular Lymphoma Grade 1 to 3a or RR Marginal Zone Lymphoma NCT04680052
LUN006 Lung NSCLC Phase 3 Randomized Study of Study DrugVersus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations  NCT04656652
LUN005 Lung NSCLC A Randomized, Open-label Phase 3 Study of Combination of Study Drug Therapies Compared with Carboplatin-Pemetrexed, in Patients with  EGFR Exon 20ins-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT04538664
MEL001 Melanoma A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Study Drug and Nivolumab Versus Nivolumab Alone, After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12) NCT04410445
MDS001 MDS High Risk A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Study Drug in Combination with Study Drug in Patients Newly Diagnosed with Higher-Risk MyelodysplasticSyndrome (Higher-Risk MDS) NCT04401748
PAN002 Pancreas A Phase 2 study to Assess the Antitumor Activity and Safety of Study Drug in Combination with another Study Drug as First Line Treatment in Subjects with Claudin 18.2 CLDN18.2 Positive, Metastatic Pancreatic Adenocarcinoma NCT03816163
STA007 Solid Tumor A Phase 2 Study of a Drug in Combination Therapies in Participants with Neuregulin-1 (NGR1) Fusion Positive Locally Advanced or Metastatic Solid Tumors NCT04383210
STA008 Solid Tumor A Phase I/II Study of Study Drug, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors (eNRGy) NCT02912949
Non Thera002 Liquid Tumor  An Observational Study to Collect and Assess Tissue Samples From Subjects with Documented Hematologic Malignancy N/A